Literature DB >> 12588208

Role of organizational factors in poor blood pressure control in patients with type 2 diabetes: the QuED Study Group--quality of care and outcomes in type 2 diabetes.

Fabio Pellegrini1, Maurizio Belfiglio, Giorgia De Berardis, Monica Franciosi, Barbara Di Nardo, Sheldon Greenfield, Sherrie H Kaplan, Michele Sacco, Gianni Tognoni, Miriam Valentini, Donatella Corrado, Antonio D'Ettorre, Antonio Nicolucci.   

Abstract

BACKGROUND: A large body of evidence supports the need for reducing the cardiovascular burden of diabetes. Only indirect and occasional data describe the adequacy of routine management of hypertension in patients with diabetes. The aim of this study was to explore the interplay of some potential key determinants of quality of antihypertensive care, including the settings, physicians' beliefs about blood pressure (BP) control, and patient-related factors.
METHODS: We evaluated physicians' beliefs about BP control using questionnaire responses at study entry. A sample of 3449 patients with type 2 diabetes mellitus, of whom 1782 (52%) were considered to have hypertension, was recruited by 212 physicians practicing in 125 diabetes outpatients clinics (DOCs) and 106 general practitioners (GPs). We evaluated the type and number of antihypertensive agents used and the BP values at study entry and after 1 year of follow-up. We used multilevel analysis to investigate correlates of poor BP control (> or =160/90 mm Hg).
RESULTS: Only 16% of GPs and 14% of DOC physicians targeted BP values of less than 130/85 mm Hg. At study entry, 6% of the patients had values below 130/85 mm Hg, whereas 52% showed values of 160/90 mm Hg or greater. Only 12% of subjects were treated with more than 2 drugs at study entry, compared with 16% at the 1-year follow-up (P =.001). Multilevel analysis showed that patients attending DOCs had a more than 2-fold increased risk for inadequate BP control, compared with those treated by GPs. The risk for poor BP control was 2 times higher for patients treated by male physicians compared with those treated by female physicians, and it was halved when the physician responsible for the diabetes care specialized in diabetology or endocrinology.
CONCLUSION: In a model situation of comorbidity, the overall quality of care depends on structural and organizational factors, which are likely to be more influential than existing guidelines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12588208     DOI: 10.1001/archinte.163.4.473

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  11 in total

Review 1.  Educational and organisational interventions used to improve the management of hypertension in primary care: a systematic review.

Authors:  Tom Fahey; Knut Schroeder; Shah Ebrahim
Journal:  Br J Gen Pract       Date:  2005-11       Impact factor: 5.386

Review 2.  Treatment and blood pressure control in 47,964 people with diabetes and hypertension: a systematic review of observational studies.

Authors:  Donna L McLean; Scot H Simpson; Finlay A McAlister; Ross T Tsuyuki
Journal:  Can J Cardiol       Date:  2006-08       Impact factor: 5.223

Review 3.  Management of hypertension and diabetes: treatment goals, drug choices, current practice, and strategies for improving care.

Authors:  Ann M Borzecki; Dan R Berlowitz
Journal:  Curr Hypertens Rep       Date:  2005-12       Impact factor: 5.369

4.  Outcomes in Older Adults with Multimorbidity Associated with Predominant Provider of Care Specialty.

Authors:  Julie P W Bynum; Chiang-Hua Chang; Andrea Austin; Don Carmichael; Ellen Meara
Journal:  J Am Geriatr Soc       Date:  2017-04-08       Impact factor: 5.562

5.  Drug management for hypertension in type 2 diabetes in family practice.

Authors:  Wayne Putnam; Farokh Buhariwalla; Kendrick Lacey; Mary Goodfellow; Rose Anne Goodine; Jennifer Hall; Ian Macdonald; Michael Murray; Preston Smith; Fred Burge; Nandini Natarajan; Beverley Lawson
Journal:  Can Fam Physician       Date:  2009-07       Impact factor: 3.275

6.  Hypertension and type 2 diabetes: what family physicians can do to improve control of blood pressure--an observational study.

Authors:  Wayne Putnam; Beverley Lawson; Farokh Buhariwalla; Mary Goodfellow; Rose Anne Goodine; Jennifer Hall; Kendrick Lacey; Ian MacDonald; Frederick I Burge; Nandini Natarajan; Ingrid Sketris; Beth Mann; Peggy Dunbar; Kristine Van Aarsen; Marshall S Godwin
Journal:  BMC Fam Pract       Date:  2011-08-11       Impact factor: 2.497

7.  Feasibility and effectiveness in clinical practice of a multifactorial intervention for the reduction of cardiovascular risk in patients with type 2 diabetes: the 2-year interim analysis of the MIND.IT study: a cluster randomized trial.

Authors:  Olga Vaccaro; Laura Franzini; Roberto Miccoli; Franco Cavalot; Diego Ardigò; Massimo Boemi; Pierpaolo De Feo; Gianpaolo Reboldi; Angela Albarosa Rivellese; Mariella Trovati; Ivana Zavaroni
Journal:  Diabetes Care       Date:  2013-07-17       Impact factor: 19.112

8.  Designing a multifaceted quality improvement intervention in primary care in a country where general practice is seeking recognition: the case of Cyprus.

Authors:  George A Samoutis; Elpidoforos S Soteriades; Henri E Stoffers; Theodora Zachariadou; Anastasios Philalithis; Christos Lionis
Journal:  BMC Health Serv Res       Date:  2008-08-27       Impact factor: 2.655

9.  A cluster randomized trial to improve adherence to evidence-based guidelines on diabetes and reduce clinical inertia in primary care physicians in Belgium: study protocol [NTR 1369].

Authors:  Liesbeth Borgermans; Geert Goderis; Carine Van Den Broeke; Chantal Mathieu; Bert Aertgeerts; Geert Verbeke; An Carbonez; Anna Ivanova; Richard Grol; Jan Heyrman
Journal:  Implement Sci       Date:  2008-10-06       Impact factor: 7.327

10.  Assessment of hypertension management in primary health care settings in Kinshasa, Democratic Republic of Congo.

Authors:  Aimée M Lulebo; Mala A Mapatano; Patrick K Kayembe; Eric M Mafuta; Paulin B Mutombo; Yves Coppieters
Journal:  BMC Health Serv Res       Date:  2015-12-24       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.